 |
Data di Nascita:
|
24 - 3 - 1961 |
|
|
Luogo di nascita:
|
Napoli |
|
|
Laurea in Medicina e Chirurgia: |
30 - 7 - 1985 |
|
110/110 e lode |
|
Facoltà di Medicina e Chirurgia, Università "Federico II" di Napoli
|
|
|
Abilitazione Medica: |
26 - 2 - 1986 |
|
Università di Napoli
|
|
|
| Esperienza: |
1983 - 1985 |
|
Allievo Interno, |
|
Cattedra di Oncologia Medica, Fac. di Med. e Chir., Univ. "Federico II" di Napoli |
|
|
|
1985 - 1988 |
|
Specializzando, |
|
Cattedra di Oncologia Medica, Fac. di Med. e Chir., Univ. "Federico II" di Napoli
|
|
|
|
1988 - 1993 |
|
Medico Interno, |
|
Cattedra di Oncologia Medica, Fac. di Med. e Chir., Univ. "Federico II" di Napoli
|
|
|
|
Dicembre 1993 |
|
Assistente, |
|
Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli
|
|
|
|
Dicembre 1995 |
|
Dirigente di I° Livello |
|
Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli
Gennaio 2001
Responsabile (Dirigente di Struttura Semplice a carattere dipartimentale)
Unità Operativa di Chemoterapia Ambulatoriale
Istituto Nazionale Tumori-Napoli
Posizione Attuale:
Dal Dicembre 2001
Direttore di Struttura Complessa U.O. Oncologia Medica, A.O.R.N. "S.G. Moscati", Avellino
Dal Dicembre 2003
Direttore del Dipartimento di Onco-Ematologia, A.O.R.N. "S.G. Moscati" Avellino
|
|
|
| Specializzazione in Oncologia: |
12 - 7 - 1988 |
|
70/70 e lode |
|
Facoltà di Medicina e Chirurgia, Università "Federico II" di Napoli
|
|
|
| Specializzazione in Medicina Interna: |
15 - 7 - 1993 |
|
Facoltà di Medicina e Chirurgia, Università "Federico II" di Napoli
|
|
|
| Attività di insegnamento: |
Professore a contratto in Oncologia Medica presso la Scuola di Specializzione in Oncologia della Università “Federico II” di Napoli dall’anno 2002.
Professore a contratto in Oncologia Medica presso la Scuola di Specializzazione in Oncologia della Seconda Università di Napoli dall’anno 2004.
Direttore della Scuola Italiana di Oncologia Toracica (SIOT) dall’anno 2008.
|
| Interessi di Ricerca: |
Tumori del Polmone, Neoplasie nell'anziano
|
|
|
| Appartenenza a Società Scientifiche: |
Associazione Italiana di Oncologia Medica (A.I.O.M.) dal 1988
Membro del Consiglio Direttivo Nazionale dal 2006 al 2007 |
|
International Association for the Study of Lung Cancer (I.A.S.L.C.) dal 2006 |
|
American Association of Clinical Oncology (A.S.C.O.) dal 1995 |
|
International Society of Geriatric Oncology (S.I.O.G.) dal 2003 al 2009
Associzione Italiana di Oncologia Toracica (AIOT), Segretario dal 2007
Euroepan Society of Medical Oncology (ESMO) dal 2008
|
| Revisore ECM |
Revisore per il Ministero della Sanità per l'EMC dal 2002
|
| Esperto Europeo EMEA |
Esperto Europeo in Oncologia per l'European Medicine Evaluation Agency (EMEA)
Londra (UK) dal 2004
|
| Appartenenza a Gruppi Cooperativi: |
Clinical Trial Promoting Group (C.T.P.G.)-Membro Consiglio Direttivo dal 2001
Chairman "Lung Cancer Section" dal 2001
|
|
European Organization for Research and Treatment of Cancer (E.O.R.T.C.)
|
|
"Lung Cancer Cooperative Group" dal 1998 al 2003
|
|
Gruppo Italiano di Oncologia Geriatrica (G.I.O.Ger)
Membro Consigio Direttivo dal 2000 al 2008
|
|
Gruppo Oncologico Italia Meridionale (G.O.I.M.)
Membro Consiglio Direttivo dal 2001
Segretario dal 2004 al 2006
|
|
International Society of Geriatric Oncology dal 2003
|
| Attività di revisore per riviste internazionali: |
European Journal of Cancer |
|
International Journal of Cancer |
|
Drugs |
|
Lung Cancer |
|
Oncology
Expert Opinion on Pharmacotherapy
Expert Review in Anticancer Therapy
Tumori
Expert Opinion in Biological Therapy
Annals of Oncology
Cancer
Clinical Cancer Research
Drugs Aging
PharmacoEconomics
Drug Safety
The Oncologist
Future Oncology
Drugs of Today
Anticancer Drugs
Chest
Cancer Therapy
Respiration
Clinical Lung Cancer
Critical Review in Oncology/Hematology
Quality of Life Research
Expert Opinion on Emerging Drugs
Drug Design, Development and Therapy
Current Medical Literature- Lung Cancer
Journal of Thoracic Oncology
Journal of Postgraduate Medicine
Cancer Chemotherapy and Pharmacology
Cancer Treatment Reviews
Therapeutics and Clinical Risk Management
Journal of Gerontology:Medical Sciences
Onkologie
European Respiratory Journal
Journal of Gerontology:Medical Sciences
Vascular Health and Risk Management
Journal of the Pancreas
Journal of Pathology
British Journal of Cancer
Journal of Geriatric Oncology
Journal of the National Cancer Institute
Journal of Clinical Oncology
Lancet Oncology
|
| Attività editoriale per riviste scientifiche: |
Cancer Report dal 1993 al 2000
Cancer Edizione Italiana dal 1999 al 2002
Critical Reviews in Oncology/Hematology dal 2000
Cancer Aging dal 2003
The Oncologists dal 2003 (Section Editors “Lung Cancer”)
Supportive and Palliative Cancer Care dal 2004
Lancet Oncology dal 2006 al 2009
Cancer dal 2006
Current Medical Literature- Lung Cancer dal 2007
Lung Cancer dal 2007
Therapeutic Advances in Medical Oncology dal 2008
Expert Opinion on Emerging Drugs dal 2009
European Journal of Clinical and Medical Oncology dal 2010
Clinical Investigation dal 2010
Journal of Geriatric Oncology dal 2010
Journal of Thoracic Disease dal 2010
World Journal of Respirology dal 2011
|
|
|
| Corsi di management: |
Corso di management per medici dirigenti di II livello "Ippocrate" effettuato presso la Scuola di Direzione Aziendale dell'Università "Luigi Bocconi" di Milano. Febbraio - Marzo - Aprile 1999. |
Autore di più di 600 pubblicazioni tra abstracts e lavori per estenso su riviste nazionali e internazionali (di cui oltre 300 su riviste internazionali indexate).
CITATION INDEX
7193 citationi su riviste internazionali indexate con h Index 40
(Publish or Perish 3 )
Il dottore Gridelli ha effettuato oltre 200 relazioni su invito e 100 moderazioni a convegni nazionali e oltre 80 relazioni su invito e 25 moderazioni a convegni internazionali.
Principali lavori pubblicati su riviste internazionali indexate:
- C. Gridelli, F. Perrone, S. Palmeri et al.: "Mitomycin C plus vindesine plus etoposide (MEV) vs mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non small cell lung cancer: a phase III multicentre randomised trial." ANNALS OF ONCOLOGY, 7:821-826, 1996.
- A. Gregor, A. Cull, R.J. Stephens, J.A. Kirkpatrik, J.R. Jarnold, D.J. Girling, .... C. Gridelli (for Naples, Italy) .....: “Prophylactic cranial irradiation following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial.” EUROPEAN JOURNAL OF CANCER, 33:1754-1760, 1997.
- C. Gridelli, F. Perrone, G.P. Ianniello et al: “Carboplatin plus vinorelbine, a new well tolerated and active regimen for the treatment of extensive-stage small cell lung cancer: a phase II study.” JOURNAL OF CLINICAL ONCOLOGY, 16:1414-1419, 1998.
- C. Gridelli, F. Perrone, C. Gallo et al. on the behalf ELVIS group. “Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer”. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 91:66-72, 1999.
- JP van Meerbeeck, P Baas, C Debruyne, HJ Groen, C Manegold, A Ardizzoni, C. Gridelli, E van Marck, M Lentz, G Giaccone for the EORTC Lung Cancer Cooperative Group. “A phase II study of gemcitabine in patients with malignant pleural mesothelioma”. CANCER, 85:2577-2582, 1999..
- L Crinò, AM Mosconi, G Scagliotti, G Selvaggi, S Noviello, M Rinaldi, M Della Giulia, C Gridelli, A Rossi, C Calandri, F De Marinis, M Noseda, M Tonato. “Gemcitabine as second line treatment for advanced non small cell lung cancer: a phase II trial”. JOURNAL OF CLINICAL ONCOLOGY, 17:2081-2085, 1999.
- L. Crinò, G.V. Scagliotti, S. Ricci, F. De Marinis, M. Rinaldi, C. Gridelli, A. Ceribelli, R. Bianco, M. Marangolo, F. Di Costanzo, M. Sari, S. Barni, A. Ravaioli, V. Adamo, L. Portalone, G. Cruciani, A. Masotti, G. Ferrara, F. Gozzelino, M. Tonato. “Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non small cell lung cancer: a randomized phase III study of the Italian Lung cancer Project. JOURNAL OF CLINICAL ONCOLOGY, 17:3522-3530, 1999.
- The Italian Group for Antiemetic Research: Rolia F, Ballatori E, Ruggieri B, De Angelis V, Tonato M, Bosnjak S, Del Favero A, ............ Gridelli C. “Dexamethasone alone or in combination with ondasetron for the prevention of delayed nausea and vomiting by chemotherapy”. NEW ENGLAND JOURNAL OF MEDICINE, 342:1554-1559, 2000.
- Gridelli C, Cortesi E, Roila F. “Editorial” “Survival and quality of life: comparing end points in oncology”. ANNALS OF ONCOLOGY, 12(SUPPL 3): S1, 2001
- Perrone F, Gallo C, Gridelli C. Re: Cisplatin – based therapy for elderly patients with advanced non small cell lung cancer: implication of Easter Cooperative Oncology Group 5592, a randomized trial. JOURNAL OF NATIONAL CANCER INSTITUTE, 94: 62-63, 2002.
- Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferraù F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Gasparini G, Daletta D, Iaffaioli RV, Gebbia V. “Chemotherapy for elderly patients with advanced non small cell lung cancer. The MILES (Multicenter Italian Lung cancer in the Elderly Study) phase 3 randomized trial. JOURNAL OF NATIONAL CANCER INSTITUTE, 95:362-72, 2003.
- Gridelli C, Maione P, Airoma G, Rossi A. “Selective cyclooxygenase-2 inhibitors and non small cell lung cancer” CURRENT MEDICINAL CHEMISTRY, 9:1851-1858, 2002.
- Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Matano E, Barni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli Aa, Clerici M, Di Coistanzo F, Frontini L, Tonato M. “Phase III randomized trial comparing three platinum doublets in advanced non small cell lung cancer”. JOURNAL OF CLINICAL ONCOLOGY, 20:4285-4291 2002.
- Gridelli C, Hainsworth J. “Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC”. LUNG CANCER 38(suppl 1):37-41, 2002.
- Gridelli C, Gallo C. Shepherd F, Illiano A, Piantedosi FV, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F. “Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trial Group”. JOURNAL OF CLINICAL ONCOLOGY, 21:3025-34, 2003.
- Gridelli C, Rossi A, Maione P. “Treatment of non small cell lung cancer: state of the art and development of new biologic agents”. ONCOGENE, 22:6629-6638, 2003.
- Gridelli C, Maione P, Rossi A. “Corticosteroids underemployement in delayed chemotherapy induced nausea and emesis with poor adherence to American Scociety of Clinical Oncology Guidelines: is this a reasonable clinical choice for the elderly?”. JOURNAL OF CLINICAL ONCOLOGY, 21:4066-4067, 2003.
- Gridelli C, Maione P, Castaldo V, Rossi A. “Gefitinib in elderly and unfit patients affected by advanced in small cell lung cancer”. BRITISH JOURNAL OF CANCER, 89:1827-1829, 2003.
- Stahel R, Rossi A, Petruzelka L, Kosmidis P, de Braud F, Bernardo M, Souquet PJ, Soto Parra H and Gridelli C. “Lessons from the Iressa expanded access programme: gefitinib in special non small cell lung cancer patient populations”. BRITISH JOURNAL OF CANCER, 89(suppl2):19-23, 2003.
- Gridelli C, Ardizzoni A., Le Chavalier T., Manegold C., Perrone F, Thatcher N, van Zandwijk N, Di Maio M, Martelli O & De Marinis F. “Treatment of advanced non small cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel”. ANNALS OF ONCOLOGY, 15:419-426, 2004.
- Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F. “Potential role of molecularly targeted therapy in the management of advanced non small cellllung carcinoma in the elderly”. CANCER, 101:1733-1744, 2004.
- Gridelli C, Manegold C, Mali P, Reck M, Portalone L, Castelnau O, Betticher D, Pless M, Pons JT, Aubert D, Burillon JP, Parlier Y, De Marinis F. “Oral Vinorelbine given as monotherapy to advanced elderly patients: a multicenter phase II trial”. EUROPEAN JOURNAL OF CANCER, 40:2424-31, 2004.
- Gridelli C, Gallo C, Di MaiooM, Barletta E, Illiano A, Maione P, Salvo S, Piantedosi FV, Palazzolo G, Caffo O, Cerebelli A, Falcone A, Mazzeo P, Brancaccio L, Captano MA, Iisa L, Barbera S, Perrone F. “A randomised clinical trial of two docetaxel regimens in the second-line treatment of non small cell lung cancer. The DISTAL 01 study.” BRITISH JOURNAL OF CANCER, 91:1996-2004, 2004.
- Perrone F, Di Maio M, Gallo C, Gridelli C. “Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES).” JOURNAL OF CLINICAL ONCOLOGY, 22:5018-20, 2004.
- Gridelli C, Maione P, Rossi A, Di Maio M,and Perrone F. “Chemotherapy of stage I to III Non-Small Cell Lung Cancer in the Elderly Patients”. AMERICAN SOCIETY OF CLINICAL ONCOLOGY, EDUCATIONAL BOOK 41ST ANNUAL MEETING 13-17 MAY 2005.-
- Gridelli C, Aapro M, Ardizzoni A, Balducci L, De Marinis F, Kelly K, Le Chevalier T, Manegold C, Perrone F, Rosell R, Shepherd F, De Pretis L, Di Maio M, Langer C. “Treatment of advanced non small cell lung cancer in the elderly: results of an International Expert Panel”. JOURNAL OF CLINICAL ONCOLOGY 23:3125-3137, 2005.
- Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, cigolari S, Manzione L; Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F. “Chemotherapy-induced neutropenia and treatment efficacy in advanced non small cell lung cancer: a pooled analysis of three randomised trias”. LANCET ONCOLOGY, 6:669-677, 2005.
- Gridelli C, Shepherd FA. “Chemotherapy for elderly patients with non small lung cancer: a review of the evidence”. CHEST, 128:947-57, 2005.
- Maione P, Perrone F, Gallo C, Manzione L, Piantedosi FV, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C. “Pretreatment qualità of life and functionallstatus assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter italian lung cancer in the elderly study.” JOURNAL OF CLINICAL ONCOLOGY, 23(28):6865-72.
- Normanno N, DeLuca A, Macello MR, Gridelli C. “Modulation of epidermal growth factor receptor positive circulating tumor cells by chemotherapy in non small cell lung cancer patients”. JOURNAL OF CLINICAL ONCOLOGY, 23:7746-8, 2005.
- Maione P, Perrone F, Gallo C, Manzione L, Piantedosi FV, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Berretto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferrau F, Frontini L, Bearz A, Repetto L, Gridelli C. “Pretreatment qualità of life and functional status assessment significantly predict survival of elderly patients with advanced non small cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter italian lung cancer in the elderly study”. JOURNAL OF CLINICAL ONCOLOGY, 23:6865-72, 2005.
- Gridelli C, Rossi A, Maione P. “New antiangiogenetic agents and non small cell lung cancer”. CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, 2006.
- Gridelli C. “The use of biphosphonate in elderly cancer patients”. THE ONCOLOGIST, 12:62-71, 2007.
- Gridelli C. “Targeted therapies and non small cell lung cancer:new developments”. CURRENT OPINION IN ONCOLOGY, 19:75-77, 2007.
- Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A. “ Sorafenib and sunitinib in the treatment of advanced non small cell lung cancer” . ONCOLOGIST, 12:191-200, 2007.
- Gridelli C. “Does palliative chemotherapy beyond three courses benefit patients with non small cell lung cancer?”. NATURE CLINICAL PRACTICE ONCOLOGY, 4:274-275, 2007.
- Gridelli C, Aapro A, Barni S, Beretta GD, Colucci G, Daniele B, Del Mastro L, Di Maio M, De Petris L, Perrone F, Thatcher N, De Marinis F. “Role of colony stimulating factors (CSFs) in solid tumors: results of an experts panel”. CRITICAL REVIEW IN ONCOLOGY/HEMATOLOGY, 63:53-64,2007.
- Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuttle W, Quoix E, Tsai CM, Gridelli C. “Individual data meta-analysis of docetaxel administered once every 3 weeks compared to once every week second-line treatment of advanced non small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 25:1377-1382, 2007.
- Gridelli C, Maione P, Rossi A. Single agent chemotherapy for the treatment of elderly patients with advanced non small cell lung cancer: what is the best drug?. JOURNAL OF CLINICAL ONCOLOGY, 25:1444-1445, 2007.
- Gridelli C, Langer C, Maione P, Rossi A, Schild S. “Lung cancer in the elderly”. JOURNAL OF CLINICAL ONCOLOGY , 25: 1898-1907, 2007.
- Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, Carrozza F, Favaretto A, Daniele B, Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Perrone F on thbehalf of the GECO Investigators.”Factorial phase III randomised trial of rofecoxib and prolonged costant infusion of gemcitabine in advanced NSCLC: the GEmcitabine ad COxib in NSCLC (GECO) study”.LANCET ONCOLOGY, 8:500-521, 2007.
- Gridelli C, Rossi A, Mongillo F, Bareschino M, Maione P, Ciardiello. “A randomised phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non small cell lung cancer in elderly patients or patients with Performance Status of 2: treatment rationale and protocol dynamics. CLIN LUNG CANCER, 8:396-398, 2007.
- Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. “Erlotinib in non small cell lung cancer treatment: current status and future development”. ONCOLOGIST, 12:840-849, 2007.
- Gridelli C, Maione P, Iliano A, Piantedosi FV, Favaretto A, Bearz A, Robbiati SF, Filipazzi V, Lo Russo V,Carozza F, Iaffaioli RV, Manzione L, Gallo C, Morabito A, Perrone F. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small cell lung cancer: the MILES phase II study. JOURNAL OF CLINICAL ONCOLOGY, 10:4663-4669, 2007.
- Gridelli C, Maione P, Rossi A, De Marinis F. The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments. ONCOLOGIST, 12:1183-1193, 2007.
- Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, Cammilluzzi E, CrinòL, De Marinis F, Di Pietro FA, Grossi F, Innocenzi D, Micali G, Piantedosi FV, Scarrozzi M.Clinical significance and treatment of skin rash from erlotinib in non small cell lung cancer patients: results of an Experts Panel Meeting. CRITICAL REVIEW IN ONCOLOGY / HEMATOLOGY, 66:155-162, 2008.
- Gridelli C, Rossi A, Morgillo F , Baraschino M, Maione P, Di Maio M, Ciardiello F. A randomised phase II study of pemetrexed or RAD001 as second-line treatment of advanced non small cell lung cancer in elderly patients: treatment rationale and protocol dynamics. CLIN LUNG CANCER, 8:568-571, 2007.
- Gridelli C. Editorial. Treatment of advanced non small cell lung cancer in the elderly: from best supportive care to the combination of platin-based chemotherapy and targeted therapies. JOURNAL OF CLINICAL ONCOLOGY, 26:13 -16 , 2008.
- Rossi A, Bria E, Gridelli C. Thalidomide in small cell lung cancer: is it a tombstone? JOURNAL OF CLINICAL ONCOLOGY, 26:160, 2008.
- Gridelli C. Targeted therapy developments in the treatment of non small cell lung cancer: a promising but long and winding road. CURRENT OPINION IN ONCOLOGY, 20:145-147,2008.
- Gridelli C, Maione P, Rossi A. The potential role of m-TOR inhibitors in non small cell lung cancer. ONCOLOGIST, 13:139-147, 2008.
- Gridelli C, Ardizzoni A, Ciardiello F, Hanna N, Heymach J, Perrone F, Rosell R, Shepherd F, Thatcher N, Vansteenkiste J, De Pretis L, Di Maio M, De Marinis F. Second-line treatment of advanced non small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 3:430-440, 2008.
- Rossi A, Torri W, Gridelli C. Paclitaxel plus bevacizumab for metastatic breast cancer. NEW ENGLAND JOURNAL OF MEDICINE, 358:1637-1638, 2008.
- Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors in the treatment of non small cell lung cancer.
CRITICAL REVIEW IN ONCOLOGY HEMATOLOGY, 68:29-36, 2008.
- Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. “An International, multicenter , randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin-gemcitabine followed by second-line erlotinib in advanced non small cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial”. CLINICAL LUNG CANCER, 9:235-238, 2008.
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Olivera AC, santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Gianniris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group….Gridelli C…. “Sorafenib in advanced hepatocellular carcinoma”. NEW ENGLAND JOURNAL OF MEDICINE, 359:378-390, 2008
- Gridelli C. Editorial “Histology-based treatment: a new era in the management of advanced non small cell lung cancer”. CURRENT OPINION IN ONCOLOGY, 21:97-98,2009.
- Di Maio M, Chiodini P, Georgouilas V, Hatzidaki D. Wachter FM, Gebbia V, Smit EF, Morabito A, Gallo C; Perrone F, Gridelli C. “Meta-analysis of single agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non small cell lung cancer”. JOURNAL OF CLINICAL ONCOLOGY, 27:1836-1843, 2009.
- Gridelli C, Maione P, Ferrara M, Rossi A. Cetuximab and other anti-epidrmal growth factors receptor monoclonal antibodies in the treatment of non small cell lung cancer. ONCOLOGIST, 14:601-611, 2009.
- Gridelli C, Rossi A,Maione P, Rossi E, Castaldo V, Sacco PC, Colantuoni G. Vascular disrupting agents: a novel mechanism of action in the battle against non small cell lung cancer. ONCOLOGIST, 14:612-620, 2009.
- Gridelli C, Maione P, Rossi A, Ferrara ML, Bareschino M, Schettino C, Sacco PC, Ciardiello F. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?
ONCOLOGIST, 14:137 – 147, 2009.
- Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, Sacco PC.Vaccines for the treatment of non small cell lung cancer: a renewed anticancer strategy. ONCOLOGIST, 14:909-920, 2009.
- Gridelli C, Haiderali AM, Russo MW, Blackburn LM, Lykopoulos. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. SUPPORTIVE CARE IN CANCER, 2009.
- Gridelli C, Ardizzoni A, Douillard YJ, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di maio M, de Marinis F. “Recent issues in first-line treatment of advanced non small cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. LUNG CANCER, 2009.
- Gridelli C, Morabito A, Gebbia V,Mencoboni M, Carroozza F, Viganò MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T, Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F. “Catuximab and gemcitabine in elderly or adult patients with advanced non small cell lung cancer: the Cetuximab in advanced lung cancer (CALC-1E and CALC,PS2) randomized phase II trials”. LUNG CANCER, 67:86-92, 2010.
- Gridelli C. “Can a decisional algorithm be used in first-line treatment of advanced non small cell lung cancer? CURRENT OPINION IN ONCOLOGY, 22:77-78, 2010.
- Gridelli C, Rossi A, Bareschino M Schettino C, Sacco PC, Maione P. “The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non small cell lung cancer”. EXPERT OPIN INVESTG DRUGS, 2010.
- Gridelli C, Rossi A, Maione P, Ambrosio R, Barbato V, Bareschino MA, Schettino C, Palazzolo G, Saco PC. “The role of maintenance treatment in advanced non small cell lung cancer: reality or early second-line?”. CLINICAL LUNG CANCER, 11:374-382, 2010.
-Gridelli C, Morgillo F. Favaretto A, De Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A, Fasano M, Pasello G, Ricciardi S, Maione P, Di Maio M, Ciardiello F. “Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non small cell lung cancer: a randomized phase II study. ANNALS OF ONCOLOGY, 2011.
- Felip E, Gridelli C, Baas P, Rosell R, Stahel R & Panel Members “Metastatic non small cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. 1 ESMO Consensus Conference in Lung Cancer; Lugano 2010. ANNALS OF ONCOLOGY, 22:1507-1519, 2011.
- Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C. “Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non small cell lung cancer after first-line treatment with bevacizumab plus platin-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. CLINICAL LUNG CANCER, 2011.
-Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, De Marinis F. “Treatment decision-making for advanced non small cell lung cancer and differencies among European countries: 1 AIOT/ETOP meeting”. LUNG CANCER, 2011.
|
|
